Investing $24 billion in developing prototype vaccines for the 26 known viral families is a proactive and essential step. This advance preparation can save countless lives and economic costs by allowing us to respond swiftly to future pandemics. The COVID-19 pandemic has shown us the critical importance of being prepared.